Search Result
Results for "
cytotoxic agent
" in MedChemExpress (MCE) Product Catalog:
5
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-144722
-
|
|
Bacterial
|
Infection
|
|
Antitubercular agent-12 (Compound 2c) is an antitubercular agent (MIC = 1.439 μg/mL). Antitubercular agent-12 shows greatly lower cytotoxicity (CC50: 57.34 μg/mL) .
|
-
-
- HY-16036A
-
|
12'-Methylthiovinblastine hydrochloride
|
Microtubule/Tubulin
|
Cancer
|
|
ALB-109564 (12'-Methylthiovinblastine) hydrochloride, a tubulin inhibitor, is a cytotoxic agent designed to kill cancer cells by disrupting mitosis .
|
-
-
- HY-13640A
-
|
GS-9219 succinate; VDC-1101 succinate
|
Others
|
Cancer
|
|
Rabacfosadine (GS-9219) succinate, a novel proagent of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells .
|
-
-
- HY-160129
-
|
ML-970; AS-I-145; NSC 716970
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Centanamycin (ML-970; AS-I-145; NSC 716970) is a novel DNA-binding agent, and shows cytotoxic activity, with an average GI50 of 34 nM in NCI-60 cell line screening .
|
-
-
- HY-N10959
-
|
|
Others
|
Cancer
|
|
4,15-Isoatriplicolide methylacrylate is a germacrane-type sesquiterpene lactone. 4,15-Isoatriplicolide methylacrylate also is a cytotoxic agent. 4,15-Isoatriplicolide methylacrylate has cytotoxic activity for MCF-7 human breast cancer cell line .
|
-
-
- HY-147293
-
|
|
Glucocorticoid Receptor
Apoptosis
Caspase
|
Cancer
|
|
Nenocorilantis a potent, orally activity glucocorticoid receptor (GR) antagonist with Ki value of 0.15 nM. Nenocorilant has pro-apoptotic effects and improves potency combined with cytotoxic agent. Nenocorilant can be used for cancer research .
|
-
-
- HY-N8394
-
|
|
Others
|
Cancer
|
|
Eupatolide is an antitumor agent that can be isolated from Eupatorium formosanum. Eupatolide has cytotoxic activity and inhibits human epidermoid carcinoma of larynx cell growth in vitro .
|
-
-
- HY-B0608
-
|
|
Bacterial
Antibiotic
Apoptosis
Necroptosis
|
Infection
Cancer
|
|
Chlorhexidine digluconate is a chlorophenyl biguanide with broad antibacterial action against both Gram (+) and (-) bacteria and fungi. Chlorhexidine digluconate is a broad-spectrum antiseptic and disinfectant. Chlorhexidine digluconate is effective to prevent and control infectious diseases of the mouth by killing bacteria in saliva and tongue. Chlorhexidine digluconate is a cytotoxic agent and induces cell necrosis and apoptosis .
|
-
-
- HY-P99152
-
|
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .
|
-
-
- HY-147806
-
|
|
Parasite
|
Infection
|
|
Antiparasitic agent-8 (Compound 9) is an antiparasitic agent against Hymenolepis nana with low cytotoxicity .
|
-
-
- HY-130083
-
|
|
ADC Cytotoxin
DNA Alkylator/Crosslinker
|
Cancer
|
|
Seco-Duocarmycin TM is a DNA alkylator agent belonging to Duocarmycins family that inhibits DNA synthesis. Seco-Duocarmycin TM is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates (ADC) [1].
|
-
-
- HY-126664
-
-
-
- HY-147971
-
|
|
Parasite
Topoisomerase
|
Infection
Cancer
|
|
Anticancer agent 75 is a potent anticancer agent. Anticancer agent 75 shows cytotoxicity and selectivity in cancer cell lines. Anticancer agent 75 shows cytotoxicity to normal human kidney cell lines is at least 35 times lower than that of the Doxorubicin standard. Anticancer agent 75 shows good activity of antiplasmodial .
|
-
-
- HY-149078
-
|
|
Parasite
|
Infection
|
|
Antiparasitic agent-14 is a potemt antiparasitic agent. Antiparasitic agent-14 shows cytotoxicity and antiparasitic activity. Antiparasitic agent-14 inhibits the growth of trypomastigote and amastigote .
|
-
-
- HY-151295
-
|
|
Others
|
Cancer
|
|
Antitumor agent-75 is a novel potent antitumor agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC50 value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer .
|
-
-
- HY-147968
-
|
|
Others
|
Cancer
|
|
Anticancer agent 74 is a moderate anticancer agent. Anticancer agent 74 has lower selectivity and cytotoxicity than doxorubicin to normal cell .
|
-
-
- HY-N11572
-
|
|
Others
|
Cancer
|
|
Anticancer agent 96 (Compound 4) is an anticancer agent that shows cytotoxic activities against human cancer cells .
|
-
-
- HY-147006
-
|
|
Others
|
Cancer
|
|
MT-VC-ZD02044 is a cytotoxic and anti-mitotic agent .
|
-
-
- HY-155278
-
|
|
Others
|
Cancer
|
|
Anticancer agent 162 (compound 1d) is an effective anticancer theranostic agent. Anticancer agent 162 induces oncosis of Hela cells with lipophilicity and cytotoxicity selectivity .
|
-
-
- HY-153051
-
|
|
Others
|
Cancer
|
|
Antitumor agent-90 (Compound 17) has cytotoxicity against PC 14 cell and MKN 45 cell. Antitumor agent-90 can be used for cancer research .
|
-
-
- HY-155067
-
|
|
Bacterial
|
Infection
|
|
Antitubercular agent-38 is an orally active Benzothiazinones (BTZs) derivate, with potent antituberculosis activity. Antitubercular agent-38 exhibits low cardiac toxicity, low cell cytotoxicity .
|
-
-
- HY-149839
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-112 (compound 3a) is a potent antitumor agent. Antitumor agent-112 induces apoptosis. Antitumor agent-112 has cytotoxic activity on A549 cells with an IC50 value of 91.35 μM .
|
-
-
- HY-128498
-
|
|
Others
|
Cancer
|
|
Anticancer agent 182 is a cytotoxic flavonoid compound isolated from the root ofMuntingia colabura L. Anticancer agent 182 exhibits anticancer activity .
|
-
-
- HY-111606
-
-
-
- HY-163089
-
|
|
Others
|
Cancer
|
|
Anticancer agent 176 (Compoint 10α) is an anticancer agent. Anticancer agent 176 exhibits excellent in vitro cytotoxic activity against neuroblastoma with an IC50 value of 6.3 μM .
|
-
-
- HY-146406
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 52 is a potent anticancer agent. Anticancer agent 52 shows in vitro cytotoxicity. Anticancer agent 52 induces apoptosis. Anticancer agent 52 shows antitumor effect. Anticancer agent 52 has the potential for the research of bladder cancer .
|
-
-
- HY-146197
-
|
|
Apoptosis
|
Cancer
|
|
Apoptotic agent-1 (Compound 8a) is an apoptotic agent with high antiproliferative activity against cancer cells and low cytotoxic effect. Apoptotic agent-1 induces over-expression of Fas receptor and Cyto C genes .
|
-
-
- HY-151236
-
|
|
Bacterial
|
Infection
|
|
Antitubercular agent-30 is an antibacterial agent against Mycobacterium tuberculosis (MIC=50 μg/mL). Antitubercular agent-30 has little cytotoxic effect on murine macrophage cells (LD85=~100 μg/mL) .
|
-
-
- HY-155546
-
|
|
Bacterial
|
Infection
|
|
Antimicrobial agent-22 (THI 6c) is a multi-target broad-spectrum antibacterial agent. Antimicrobial agent-22 has low cytotoxicity, hemolytic property, rapid bactericidal ability and good anti-biofilm activity .
|
-
-
- HY-139705
-
|
|
Others
|
Cancer
|
|
Anticancer agent 12 is unexpectedly devoids of hepatotoxicity while maintaining cytotoxic activity in malignant cells.
|
-
-
- HY-149956
-
|
|
Parasite
|
Infection
|
|
Antileishmanial agent-15 (compound 13c) is a potent antileishmanial agent. Antileishmanial agent-15 shows antileishmanial and cytotoxic activity against L. major promastigotes and amastigotes, with IC50 values of 0.78 and 0.99 μM, respectively .
|
-
-
- HY-151121
-
|
|
Others
|
Cancer
|
|
Anticancer agent 80 (Compound 3c) is an anticancer agent. Anticancer agent 80 exhibits the dark cytotoxicity against T47-D with IC50 of 10.14 µM .
|
-
-
- HY-151119
-
|
|
Cytochrome P450
|
Cancer
|
|
Anticancer agent 78 is a potent anticancer agent. Anticancer agent 78 shows cytotoxicity. Anticancer agent 78 exhibits anti-aromatase activity with an IC50 value of 0.9 µM. Anticancer agent 78 has the potential for the research of breast cancer .
|
-
-
- HY-151356
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 122 (compound 15) is a thiourea derivative with anti-mycobacterial activity and low cytotoxicity. Antibacterial agent 122 can be used for tuberculosis-related studies .
|
-
-
- HY-151564
-
|
|
Others
|
Cancer
|
|
Anticancer agent 85 (compound 6j) is an anticancer agent that shows good cytotoxicity against MCF7 cells. Anticancer agent 85 can be used in breast cancer and other cancer studies .
|
-
-
- HY-13767
-
|
SR259075; SR4233; Win59075; SML 0552; SR 259075; Tirazone
|
DNA/RNA Synthesis
|
Cancer
|
|
Tirapazamine (SR259075) is an anticancer agent that shows selective cytotoxicity for hypoxic cells in solid tumors, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death. Tirapazamine is an anticancer and bioreductive agent.Tirapazamine (SR259075) can enhance the cytotoxic effects of ionizing radiation in hypoxic cells .
|
-
-
- HY-149840
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-113 shows cytotoxic effects on A549 cells with IC50 value of 46.60 μM and induces apoptosis. Antitumor agent-113 can be used in non-small cell lung cancer study .
|
-
-
- HY-147534
-
|
|
Parasite
|
Infection
|
|
Antileishmanial agent-6 (compound 8m) is a potent antileishmanial agent. Antileishmanial agent-6 shows antileishmanial and cytotoxic activity against Leishmania donovani and L-6, with IC50 values of 0.54 and 10.2 μM, respectively .
|
-
-
- HY-146286
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 44 (compound 2a) is a potent anticancer agent. Anticancer agent 44 shows cytotoxicity activity in cancer cells. Anticancer agent 44 induces apoptosis. Anticancer agent 44 shows low toxicity towards activated lymphocytes of human blood .
|
-
-
- HY-155167
-
|
|
Antibiotic
Fungal
|
Cancer
|
|
Anticancer agent 151 (compound 6C) is an anticancer agent. Anticancer agent 151 exhibits excellent in vitro cytotoxic activity against MCF-7 cells with an IC50 value of 6.3 μM .
|
-
-
- HY-161258
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 181 (Compound 3f) is a potent ciprofloxacin cationic antibacterial agent with low cytotoxicity. The MIC values of Antibacterial agent 181 against Staphylococcus aureus and Escherichia coli are both 2 μg/mL .
|
-
-
- HY-147538
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-64 (Compound 8d) is a diosgenin derivative. Antitumor agent-64 exhibits potent cytotoxic activity against A549 cell line. Antitumor agent-64 induces A549 cells apoptosis via the mitochondria-related pathway .
|
-
-
- HY-146417
-
|
|
Flavivirus
|
Infection
|
|
Antiviral agent 19 (Compound 3) is a selective inhibitor against Zika virus infection with an EC50 of 1.3 µM. Antiviral agent 19 has low cytotoxicity .
|
-
-
- HY-137773
-
|
|
Drug Metabolite
|
Cancer
|
|
N-Methyl pemetrexed is an impurity of Pemetrexed. Pemetrexed is an antifolate cytotoxic agent that can be used for the research of cancer .
|
-
-
- HY-147871
-
|
|
Bacterial
|
Infection
|
|
Antimycobacterial agent-3 (Compound 1h) is an antimycobacterial agent against both agent-sensitive MTB strain H37Rv and drug-resistant clinical isolates (MIC: < 0.029–0.110 μM). Antimycobacterial agent-3 shows low cell cytotoxicity .
|
-
-
- HY-157454
-
|
|
Others
|
Infection
|
|
Antiviral agent 48 (compound 9m) is a pan-antiviral agent. Antiviral agent 48 has anti-HEV activity and cytotoxicity (EC90=30.6 nM; CC50=13.8 nM) .
|
-
-
- HY-146290
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 46 (compound 2b) is a potent and selective anticancer agent. Anticancer agent 46 shows cytotoxicity activity in cancer cells. Anticancer agent 46 induces apoptosis. Anticancer agent 46 shows low toxicity towards activated lymphocytes of human blood .
|
-
-
- HY-146418
-
|
|
Flavivirus
|
Infection
|
|
Antiviral agent 20 (Compound 17b) is a selective inhibitor against Zika virus infection with an EC50 of 4.5 µM. Antiviral agent 20 has low cytotoxicity .
|
-
-
- HY-145908
-
|
|
Others
|
Cancer
|
|
Antitumor agent-49 (Compound 10) is a Harmine derivative-furoxan hybrids containing NO donor, with antitumor activities. Antitumor agent-49 shows cytotoxic activity against HepG2 cells with an IC50 of 1.79 µM. Antitumor agent-49 produces high levels of NO in vitro .
|
-
-
- HY-N3741
-
|
Didrovaltratum
|
Others
|
Cancer
|
|
Didrovaltrate (Didrovaltratum) can be isolated from the roots of Valeriana wallichii D.C. Didrovaltrate is an antitumor agent with cytotoxicity .
|
-
- HY-101127
-
|
PBD dimer
|
ADC Cytotoxin
|
Cancer
|
|
SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.
|
-
- HY-143641
-
|
|
Others
|
Cancer
|
|
Anticancer agent 25 exhibits the strongest cytotoxicity against PC3 cells with an IC50 value of 0.19 μM.
|
-
- HY-146407
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 53 is a potent anticancer agent. Anticancer agent 53 shows in vitro cytotoxicity. Anticancer agent 53 induces apoptosis and cell cycle arrest in S/G2/M phases. Anticancer agent 53 shows antitumor activity with no apparent toxicity .
|
-
- HY-N12142
-
|
|
Others
|
Cancer
|
|
Anticancer agent 156 (compound 11) is a powerful anticancer agent based on Miliusanes (anticancer lead molecule). Anticancer agent 156 effectively inhibits the growth of human cancer cells and shows significant cytotoxicity to gastric cancer cells .
|
-
- HY-148180
-
|
|
Bacterial
Parasite
|
Infection
|
|
Antimycobacterial agent-4 is a 2-amino-4-(2-pyridyl) thiazole derivative, with antimycobacterial activity, antiplasmodial activity, and cytotoxicity on a mammalian cell line .
|
-
- HY-155413
-
|
|
Apoptosis
|
Cancer
|
|
Antiproliferative agent-43 (Compound e4 ) has notable cytotoxic effects against cancer cell lines and causes apoptosis by stopping the cell cycle at G1 phase .
|
-
- HY-146496
-
|
|
Bacterial
|
Infection
|
|
Antitubercular agent-20 (Compound 2d) is an orally active antitubercular agent. Antitubercular agent-20 shows excellent activity against MTB H37Rv and MDR-MTB strains (MIC: ＜0.016 µg/ml). Antitubercular agent-20 has low cytotoxicity and good tolerance in BALB/c mice .
|
-
- HY-147505
-
|
|
Bacterial
Fungal
|
Infection
|
|
Antitubercular agent-21 (Compound 15) is an antitubercular agent with an MIC of o.4 µg/mL against M. tuberculosis H37Rv. Antitubercular agent-21 exhibits lower activity against other microorganism such as bacteria gram-positive, gram-negative or fungi. Antitubercular agent-21 shows low cytotoxicity .
|
-
- HY-149938
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 25 is an orally active 1,4-naphthoquinones derivative with antimalarial activity. Antimalarial agent 25 shows cytotoxicity against P. falciparum. Antimalarial agent 25 inhibits P. burghei induced parasitemia in vivo .
|
-
- HY-149353
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 145 (compound 1b) is an antibacterial agent depending on bacterial iron uptake pathway. Antibacterial agent 145 disrupts cytoplasmic membrane integrity and inhibits cell metabolism but exhibits low cytotoxic effects to normal cells .
|
-
- HY-13640
-
|
GS-9219; VDC-1101
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rabacfosadine (GS-9219), a novel proagent of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells.
|
-
- HY-121649
-
|
|
Topoisomerase
|
Cancer
|
|
AQ4 is a topoisomerase II inhibitor and DNA intercalator as a chemically stable cytotoxic agent in many human tumor lines .
|
-
- HY-149986
-
|
|
Parasite
|
Infection
|
|
Antitrypanosomal agent 13 (compound 4b) is a potent antitrypanosomal agent. Antitrypanosomal agent 13 has trypanocidal and cytotoxic activity with GI50 values of 0.18 and 8.4 μM for T. brucei and HL-60, respectively .
|
-
- HY-162239
-
|
|
Others
|
Cancer
|
|
Anticancer agent 187 (Compound 4) is an anticancer agent that can target sarcoma cells in tumor-bearing mouse models. Anticancer agent 187 exhibits cytotoxic activity against HepG2, Caco2, and MCF-7 cells .
|
-
- HY-146495
-
|
|
Bacterial
|
Infection
|
|
Antitubercular agent-19 (Compound 1c) is an antitubercular agent. Antitubercular agent-19 shows excellent activity against MTB H37Rv and MDR-MTB strains (MIC: ＜0.016 µg/ml). Antitubercular agent-19 shows low cytotoxicity and relatively high acute lethal toxicity in BALB/c mice .
|
-
- HY-147704
-
|
|
Bacterial
|
Infection
|
|
Antimycobacterial agent-2 (compound 58) is a potent antimycobacterial agent. Antimycobacterial agent-2 shows anti-mycobacterial activities with an MIC99 of 0.8 µM for Mycobacterium tuberculosis (M.tb) H37Rv. Antimycobacterial agent-2 shows cytotoxic activities with an IC50 of48.1 µM for CHO cells .
|
-
- HY-115949
-
|
|
Others
|
Cancer
|
|
Antitumor agent-47 (Compound 3e) is a silibinin derivative with an antitumor activity. Antitumor agent-47 shows cytotoxic activity against NCI-H1299 and HT29 cells with IC50 values of 8.07 µM and 6.27 µM, respectively .
|
-
- HY-149805
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 110 is an anticancer agent with in vitro anticancer activity and excellent anti-leukemia potency. Anticancer agent 110 is highly cytotoxic to K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. Anticancer agent 110 causes DNA damage and leads to apoptosis .
|
-
- HY-W028690
-
DNMDP
3 Publications Verification
|
Phosphodiesterase (PDE)
|
Cancer
|
|
DNMDP, a phosphodiesterase 3A (PDE3A) inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity .
|
-
- HY-156186
-
|
|
Others
|
Cancer
|
|
Anticancer agent 160 (Compound 6) is a natural product derived from Parthenium hysterophorus. Anticancer agent 160 is cytotoxic to HCT-116 cells, IC50=5.0 μM .
|
-
- HY-N11919
-
|
|
Others
|
Cancer
|
|
Anticancer agent 149 (compound 3) is an anticancer agent isolated from the rhizome of Dioscorea dioscorea (DM). Anticancer agent 149 exhibits selective cytotoxic activity against MCF-7 cells (IC50=31.41 μM) .
|
-
- HY-14941
-
|
CP 4055
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Elacytarabine (CP 4055) is a lipid-conjugated derivative of the nucleoside analog cytarabine. Elacytarabine (CP 4055) is an antineoplastic agent with cytotoxicity in solid tumors.
|
-
- HY-N8198
-
|
|
Apoptosis
Ferroptosis
|
Cancer
|
|
Ardisiacrispin B displays cytotoxic effects in multi-factorial agent resistant cancer cells via ferroptotic and apoptotic cell death .
|
-
- HY-158108
-
|
|
Autophagy
Ferroptosis
Reactive Oxygen Species
|
Cancer
|
|
anti-TNBC agent-6 (compound pt-3) is a potent anti-TNBC agent. anti-TNBC agent-6 shows cytotoxic activity. anti-TNBC agent-6 induces autophagy and ferroptosis. anti-TNBC agent-6 enhances intracellular ROS accumulatio. anti-TNBC agent-6 shows anti tumor activity and has the potential for the research of breast cancer .
|
-
- HY-147970
-
|
|
Fungal
|
Infection
|
|
Antifungal agent 34 (compound 6i) is a potent antifungal agent. Antifungal agent 34 shows a potent antifungal activity against Candida albicans, with a MIC of 4 µg/mL. Antifungal agent 34 shows significant inhibition on Candida albicans hyphae and biofilm development. Antifungal agent 34 exhibits no cytotoxicity to mammalian cells .
|
-
- HY-146044
-
|
|
Parasite
|
Infection
|
|
Antiparasitic agent-6 (compound 5b) has selectively antiparasitic activity against Leishmania infantum (L. infantum) with an IC50 value of 3.89 μM. Antiparasitic agent-6 also has certain cytotoxicity against HepG2 (CC50 = 13.64 μM) .
|
-
- HY-146043
-
|
|
Parasite
|
Infection
|
|
Antiparasitic agent-5 (compound 8h) has selectively antiparasitic activity against Leishmania infantum (L. infantum) with an IC50 value of 2.50 μM. Antiparasitic agent-5 also has certain cytotoxicity against HepG2 (CC50 = 6.78 μM) .
|
-
- HY-146045
-
|
|
Parasite
|
Infection
|
|
Antiparasitic agent-7 (compound 5d) has selectively antiparasitic activity against Leishmania infantum (L. infantum) with an IC50 value of 2.85 μM. Antiparasitic agent-7 also has certain cytotoxicity against HepG2 (CC50 = 10.61 μM) .
|
-
- HY-147537
-
|
|
Parasite
|
Infection
|
|
Antileishmanial agent-9 (compound 16c) has potent and selective activity against Leishmania donovani (L. donovani) with an IC50 value of 4.01 μM. Antileishmanial agent-9 has relatively low cytotoxicity in L-6 cells (IC50 = 40.1 μM) .
|
-
- HY-142545
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 68 (compound 4d) is an antibacterial agent against drug-resistant Escherichia coli. Antibacterial agent 68 has low cytotoxicity and exerts strong antibacterial activities against multidrug-resistant Escherichia coli at low concentrations as 0.007 mM .
|
-
- HY-155711
-
|
|
Fungal
|
Infection
|
|
Antifungal agent 69 (compound 13) is a eugenol-imidazole against Candida albicans (MIC: 4.6 μM) with no relevant cytotoxicity. Antifungal agent 69 alters the fungal ergosterol biosynthesis and shows antifungal activity .
|
-
- HY-161171
-
|
|
Parasite
Ephrin Receptor
|
Cancer
|
|
Antimalarial agent 37 (compound 33) is a selective inhibitor against Type Ⅱ kinase with antiplasmodial activity. Antimalarial agent 37 exhibited cytotoxicity and selectivity towards cancer cells HepG2 and MCF 7 .
|
-
- HY-147536
-
|
|
Parasite
|
Infection
|
|
Antileishmanial agent-8 (compound 18) has potent and selective activity against Leishmania donovani (L. donovani) with an IC50 value of 5.64 μM. Antileishmanial agent-8 has relatively low cytotoxicity in L-6 cells (IC50=73.9 μM) .
|
-
- HY-146104
-
|
|
Bacterial
|
Infection
|
|
Antimycobacterial agent-1 (compound 33) has selectively antimycobacterial activity against Mycobacterium tuberculosis (M. tuberculosis) H37Ra with a MIC value of 1 μg/ml. Antimycobacterial agent-1 has relatively low cytotoxicity in normal cells (Vero cells IC50 = 143.2 μg/ml) .
|
-
- HY-155402
-
|
|
Caspase
Apoptosis
|
Others
|
|
Antiproliferative agent-42 (compound 7m) is a dihydrodipyrrolo compound. Antiproliferative agent-42 showed antiproliferative activity against Panc-1 cell line with an IC50 value of 12.54 μM .
|
-
- HY-149939
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 26 is an orally active 1,4-naphthoquinones derivative with antimalarial activities. Antimalarial agent 26 shows cytotoxicity against P. falciparum and selectivity over mammalian cell lines. Antimalarial agent 26 inhibits P. burghei induced parasitemia in vivo .
|
-
- HY-146389
-
|
|
MDM-2/p53
P-glycoprotein
|
Cancer
|
|
Anticancer agent 50 (compound 6) is a potent ABCB1 efflux pump modulator. Anticancer agent 50 shows cytotoxic effects and antiproliferative effects. Anticancer agent 50 decreases the expression of cyclin D1 and induces p53 expression. Anticancer agent 50 has the potential for the research of T-lymphoma .
|
-
- HY-149344
-
|
|
Apoptosis
Autophagy
EGFR
|
Cancer
|
|
Anticancer agent 133 (compound Rh2) is an anti-cancer agent with cytotoxic and antimetastatic activities. Anticancer agent 133 induces cell cycle arrest, apoptosis, and autophagy. Anticancer agent 133 also inhibits cell metastasis via suppression of EGFR expression mediated by FAK-regulated integrin β1 .
|
-
- HY-N7990
-
|
|
Others
|
Neurological Disease
|
|
Scheffoleoside A is a neuroprotective agent can be derived from Centella asiatica. Scheffoleoside A exhibits moderate activity in inhibiting 6-OHDA-induced cytotoxicity .
|
-
- HY-147884
-
|
|
Bacterial
|
Infection
|
|
Antitubercular agent-28 (compound 2) is a potent antitubercular agent with an IC50 value of 1.5 µM, an MIC value of 4.5 µM, an IC90 value of 2.5 µM. Antitubercular agent-28 shows antimycobacterial activity for resistant isolates of Mycobacterium tuberculosis H37Rv. Antitubercular agent-28 shows effective intracellular antimycobacterial activity and low cytotoxicity .
|
-
- HY-147883
-
|
|
Bacterial
|
Infection
|
|
Antitubercular agent-27 (compound 1) is a potent antitubercular agent with an IC50 value of 3.2 µM, an MIC value of 7.8 µM, an IC90 value of 7.0 µM. Antitubercular agent-27 shows antimycobacterial activity for resistant isolates of Mycobacterium tuberculosis H37Rv. Antitubercular agent-27 shows effective intracellular antimycobacterial activity and low cytotoxicity .
|
-
- HY-146348
-
|
|
Bacterial
|
Infection
|
|
Tuberculosis inhibitor 5 (Compound 11i) is a potent antimycobacterial biphenyl analogue without noticeable cytotoxicity. Tuberculosis inhibitor 5 is an anti-tuberculosis agent .
|
-
- HY-146547
-
|
|
Interleukin Related
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-inflammatory agent 17 is a potent and orally active anti-inflammatory agent. Anti-inflammatory agent 17 inhibits the release of IL-6 and TNF-α in vitro experiments without cytotoxicity. Anti-inflammatory agent 17 exhibits anti-inflammatory activity in vivo. Anti-inflammatory agent 17 has the potential for the research of Acute lung injury (ALI) .
|
-
- HY-146078
-
|
|
Bacterial
|
Infection
|
|
Antimicrobial agent-1 (compound 6C) possesses potent activity against TolC mutant E. coli with an MIC value of 2 μg/mL. Antimicrobial agent-1 and Colistin exhibit synergistic activity against Gram-negative bacteria. Antimicrobial agent-1 has no cytotoxicity on mammalian cell lines, with MICs > 128 μg/mL in Caco-2 and Vero cell lines .
|
-
- HY-146057
-
|
|
Bacterial
|
Infection
|
|
Antituberculosis agent-2 (Compound 8d) is an antituberculosis agent against agent-sensitive and multidrug-resistant tuberculosis. Antituberculosis agent-2 shows anti-tuberculosis activity with MIC values of 0.454, 1.757 and 1.644 μg/mL against M. tuberculosis H37Rv, 13946 and 14862, respectively. Antituberculosis agent-2 displays favorable mouse and human microsomal stability, low cytotoxicity, and acceptable oral bioavailability .
|
-
- HY-161330
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 10 (Compound 2d) is a Cephalosporin (HY-144229) derivative and exhibits antibacterial activity. Anti-MRSA agent 10 is slightly drug resistane and exhibits low cytotoxicity in cells HUVEC and HBZY-1 .
|
-
- HY-12456
-
|
|
Antibiotic
ADC Cytotoxin
DNA Alkylator/Crosslinker
Necroptosis
Apoptosis
|
Cancer
|
|
Duocarmycin SA is an orally active antitumor antibiotic with an IC50 of 10 pM . Duocarmycin SA is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA. Duocarmycin SA demonstrates synergistic cytotoxicity against glioblastoma multiforme (GBM) cells treated with proton radiation in vitro .
|
-
- HY-N4322
-
|
|
PKC
|
Inflammation/Immunology
Cancer
|
|
Decursinol angelate, a cytotoxic and protein kinase C (PKC) activating agent from the root of Angelica gigas, possesses anti-tumor and anti-inflammatory activities .
|
-
- HY-14769
-
|
5,10-Methylenetetrafolate; ANX-510 free acid
|
Endogenous Metabolite
|
Cancer
|
|
Folitixorin (5,10-methylenetetrahydrofolate) is a cofactor and an analog of leucovorin. Folitixorin is a promising agent for modulation of 5-FU cytotoxicity in adjuvant cancer research .
|
-
- HY-147514
-
|
|
Apoptosis
Caspase
PARP
Bcl-2 Family
|
Cancer
|
|
Anticancer agent 64 (compound 5m) shows cytotoxic activity in CCRF-CEM cells, with IC50 of 2.4 μM. Anticancer agent 64 shows good anticancer activity through apoptosis induction. Anticancer agent 64 induces caspase 3 and 7 activation and PARP cleavage. Anticancer agent 64 induces significant effect of mitochondria depolarization .
|
-
- HY-157487
-
|
|
Others
|
Cancer
|
|
Anticancer agent 185 (compound 9d) is a glycohybrid derivative of pyrazolopyrimidine [1,5-a]. Anticancer agent 185 has good anti-breast cancer activity. Anticancer agent 185 shows good cytotoxic activity against MCF-7 cells with IC50 value of 15.3 μM .
|
-
- HY-151120
-
|
|
Others
|
Cancer
|
|
Anticancer agent 79 (compound 3d) shows good anti-breast cancer activity. Anticancer agent 79 shows good cytotoxic activity in T47-D cells, with an IC50 of 13.64 ± 0.26 μM .
|
-
- HY-158019
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Anticancer agent 196 (compound 1) shows cell cytotoxicity with IC50 values of 7.69 µM and 54.2 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 196 can induce DNA damage .
|
-
- HY-149013
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 5 (B14) is a potent MRSAagent with MIC50 values of 0.38 μg/mL and has low hERG activity with an IC50 values of >40 μM. Anti-MRSA agent 5 (B14) also has low cytotoxicity to mammal cells and unlikely to acquire bacterial resistance .
|
-
- HY-14907
-
|
MPC 6827
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Verubulin (MPC-6827) is a microtubule-disrupting agent with potent and broad-spectrum in vitro and in vivo cytotoxic activities, and acts as a promising candidate for the treatment of multiple cancer types .
|
-
- HY-116786
-
|
|
Others
|
Cancer
|
|
11-Hydroxycanthin-6-one, a canthin-6-one alkaloid, is an antitumor agent which shows potent cytotoxic activity .
|
-
- HY-122944
-
|
|
Others
|
Cancer
|
|
20-Deoxocarnosol (compound 7) is a potent anti-cancer agent that can be found in the roots of Salvia deserta. 20-Deoxocarnosol shows cytotoxicity in cancer cells .
|
-
- HY-N7572
-
|
|
Parasite
|
Infection
|
|
Eupatoriopicrin is an antitrypanosomic agent with an IC50 value of 1.2 μM (T. b. rhodesiense). Eupatoriopicrin is cytotoxic to L6 cells with an IC50 value of 1.6 μM .
|
-
- HY-N12525
-
|
|
Others
|
Inflammation/Immunology
|
|
Bartsioside is an anti-inflammatory agent which can be extracted from C. deserticola. Bartsioside exerts no significant cytotoxicity under 40 μM to BV-2 cells .
|
-
- HY-146428
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 4 (compound 7a) is a potent and selective growth inhibitor of Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA), with MIC ≤ 0.26 µM. Anti-MRSA agent 4 exhibits no cytotoxic and no hemolytic activity in HEK293 cells .
|
-
- HY-158020
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Anticancer agent 197 (compound 2b) shows cell cytotoxicity with IC50 values of 10.03 µM and 73.54 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 197 can induce DNA damage .
|
-
- HY-115905
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 9 (Compound 11) is a potent antimalarial agent. Antimalarial agent 9 is a quinoline-imidazole derivative compound. Antimalarial agent 9 exhibits significant antimalarial efficacy in-vitro against both CQ-sensitive (IC50-0.14 μM) and MDR strain (IC50-0.41 μM) with minimal cytotoxicity and high selectivity .
|
-
- HY-146042
-
|
|
Parasite
|
Infection
|
|
Antiparasitic agent-4 (compound 4q) has highly antiparasitic activity against Leishmania infantum (L. infantum) and Trypanosoma cruzi (T. cruzi) with IC50s of 8.51 μM and 2.20 μM, respectively. Antiparasitic agent-4 also has certain cytotoxicity against HepG2 (CC50 = 18.97 μM) .
|
-
- HY-146041
-
|
|
Parasite
|
Infection
|
|
Antiparasitic agent-2 (compound 8a) has highly antiparasitic activity against Leishmania infantum (L. infantum) and Trypanosoma cruzi (T. cruzi) with IC50s of 7.28 μM and 2.30 μM, respectively. Antiparasitic agent-2 also has certain cytotoxicity against HepG2 (CC50 = 26.79 μM) .
|
-
- HY-143232
-
|
|
Fungal
Bacterial
|
Infection
Cancer
|
|
Antibacterial agent 73 (compound 7a) is a potent antimicrobial agent. Antibacterial agent 73 exhibits very good antitubercular activity (MIC=0.65 µg/mL) against Mtb H37Rv. Antibacterial agent 73 shows good activity against fungal and bacterial. Antibacterial agent 73 also shows cytotoxicity in MCF-7 breast cancer cell lines, with IC50 of 8.20 μM .
|
-
- HY-151799
-
|
|
p62
E1/E2/E3 Enzyme
|
Cancer
|
|
Antitumor agent-81 (compound 5a) is a low cytotoxic P62-RNF168 agonist that promotes the interaction of P62 with RNF168. Antitumor agent-81 induces a decrease in RNF168-mediated H2A ubiquitination and impairs homologous recombination-mediated DNA repair. Antitumor agent-81 also inhibits mice xenograft tumor growth in a dose-dependent manner .
|
-
- HY-101162
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SGD-1910 is a agent-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala .
|
-
- HY-19118
-
|
FFC14A
|
Apoptosis
|
Cancer
|
|
KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells .
|
-
- HY-N10304
-
|
|
Apoptosis
|
Cancer
|
|
Isodispar B is an anticancer agent that inhibits the proliferation of nasopharyngeal carcinoma and breast cancer cells and induces cell apoptosis. Isodispar B is cytotoxic to a wide range of cancer cell lines .
|
-
- HY-149985
-
|
|
Parasite
|
Infection
|
|
Antitrypanosomal agent 12 is a C20-phenylthiourea with trypanocidal and cytotoxic activities. Antitrypanosomal agent 12 shows antitrypanosomal activity with 50% growth inhibition (GI50) values of 0.22 μM. Antitrypanosomal agent 12 induces faster cell swelling in bloodstream-form trypanosomes than Salinomycin (HY-15597) .
|
-
- HY-P9968
-
|
|
EGFR
|
Cancer
|
|
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
- HY-115950
-
|
|
Others
|
Cancer
|
|
Antitumor agent-48 (Compound 4a) is a 2,3-dehydrosilybin derivative with an antitumor activity. Antitumor agent-48 shows cytotoxic activity against MCF-7, NCI-H1299, HepG2 and HT29 cells with IC50 values of 8.06 µM, 13.1 µM, 16.51 µM and 12.44 µM, respectively .
|
-
- HY-146421
-
|
|
NO Synthase
NF-κB
Reactive Oxygen Species
|
Inflammation/Immunology
|
|
Anti-inflammatory agent 21 (compound 9o) is an orally active and low cytotoxic anti-inflammatory agent, with an IC50 value of 0.76 μM for NO. Anti-inflammatory agent 21 acts via accumulation ROS and blocks the NF-κB/MAPK signaling pathway. Anti-inflammatory agent 21 can ameliorate cartilage destruction and inflammatory cell infiltration in arthritis rats model .
|
-
- HY-U00279
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Nitracrine inhibits RNA synthesis and covalently, reversibly binds to DNA but also forms covalent adducts with DNA in vivo. Nitracrine, a 1-nitroacridine derivative, is a potent hypoxia-selective agent in vitro and antitumor agent. Nitracrine has cytotoxicity towards most cells .
|
-
- HY-U00279A
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Nitracrine (dihydrochloride hydrate) inhibits RNA synthesis and covalently, reversibly binds to DNA but also forms covalent adducts with DNA in vivo. Nitracrine (dihydrochloride hydrate), a 1-nitroacridine derivative, is a potent hypoxia-selective agent in vitro and antitumor agent. Nitracrine (dihydrochloride hydrate) has cytotoxicity towards most cells .
|
-
- HY-146556
-
|
|
Bacterial
|
Infection
|
|
Antitubercular agent-15 (Compound 5n) is an antitubercular agent with MIC90 values of 0.73, 7.69, 9.38, 18.80, 7.53 and 7.31 μg/mL against M. tuberculosis H37Rv, CF16, CF61, CF76, CF152 and CF161, respectively. Antitubercular agent-15 shows low cytotoxicity against macrophages and pulmonary fibroblasts .
|
-
- HY-146557
-
|
|
Bacterial
|
Infection
|
|
Antitubercular agent-16 (Compound 5q) is an antitubercular agent with MIC90 values of 0.40, 20.11, 23.51, 19.62, 10.93 and 13.62 μg/mL against M. tuberculosis H37Rv, CF16, CF61, CF76, CF152 and CF161, respectively. Antitubercular agent-16 shows low cytotoxicity against macrophages and pulmonary fibroblasts .
|
-
- HY-144632
-
|
|
Fungal
|
Infection
|
|
Antifungal agent 22 (compound D16) is a potential and orally active antifungal agent for CM (cryptococcal meningitis), with an IC50 of 0.5 μg/mL. Antifungal agent 22 can penetrate the blood-brain barrier and kill the C. neoformans H99 cells by destroying the integrity of fungal cell membranes. Antifungal agent 22 shows selective anti-Cryptococcus activity with good metabolic stability and low cytotoxicity .
|
-
- HY-147816
-
|
|
Mitochondrial Metabolism
|
Cancer
|
|
Anticancer agent 70 (Compound 21), an anticancer agent, exhibits remarkable cytotoxic activity against numerous human cancer cell lines. Anticancer agent 70 results in the G0/G1-cell cycle arrest with a concomitant increase in p53 and p21 protein levels. Anticancer agent 70 leads to ATP depletion and disruption of the mitochondrial membrane potential .
|
-
- HY-100875
-
|
CL216942
|
Topoisomerase
|
Cancer
|
|
Bisantrene is a highly effective antitumor agent, it exerts its cytotoxicity by affecting DNA intercalation. Bisantrene targets eukaryotic type II topoisomerases. Bisantrene is a substrate of MDR1 .
|
-
- HY-N6997
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Ceratamine A is an antimitotic heterocyclic alkaloid isolated from the marine sponge Pseudoceratina sp., acts as a microtubule-stabilizing agent. Ceratamine A exhibits cytotoxicity against human cancer cell lines .
|
-
- HY-N2877
-
-
- HY-101150
-
|
|
DNA Alkylator/Crosslinker
ADC Cytotoxin
|
Cancer
|
|
DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
|
-
- HY-100875A
-
|
CL-216942 dihydrochloride
|
Topoisomerase
|
Cancer
|
|
Bisantrene dihydrochloride is a highly effective antitumor agent, it exerts its cytotoxicity by affecting DNA intercalation. Bisantrene dihydrochloride targets eukaryotic type II topoisomerases. Bisantrene dihydrochloride is a substrate of MDR1 .
|
-
- HY-N3041
-
|
Agoniadin; NSC 609065
|
Fungal
|
Infection
Cancer
|
|
Plumieride is an antifungal agent. Plumieride has strong fungitoxicity against some dermatophytes. Plumieride has little cytotoxic activity against the P388 leukaemia cell line with an IC50 of 85 μg/mL .
|
-
- HY-113860
-
|
|
HCV
|
Infection
|
|
Antiviral agent 52 (Compound 30) is a Chlorcyclizine (HY-112067) derivative that exhibits antiviral activity against hepatitic C virus (HCV) with an EC50 of 17 nM. Antiviral agent 52 reveals cytotoxicity in cell Huh7.5.1 with CC50 of 21.3 μM .
|
-
- HY-155354
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 33 (compound 5g) has antiplasmodial activity against erythrocytic and hepatic stages of Plasmodium with an EC50 of 1.1 μM for K1 P. falciparum strain. Antimalarial agent 33 demonstrats enhanced microsomal stability (T1/2=29 min). Antimalarial agent 33 has no significant cytotoxicity against primary hepatocytes .
|
-
- HY-N10332
-
|
|
Proteasome
|
Cancer
|
|
Leptosphaerodione, isolated from Remotididymella sp. Fungus, is a potent ubiquitin-proteasome system (UPS) inhibitor. Leptosphaerodione exhibits cytotoxicity in HeLa cells with IC50 value of 3.2 μM. Anti-tumor agent .
|
-
- HY-145989
-
|
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
|
-
- HY-144822
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 2 (compound 14) has highly inhibitory activity against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.098 μg/ml, and relatively low cytotoxicity in normal cells. Anti-MRSA agent 2 has strong ability to destroy bacterial membrane and bind to genomic DNA .
|
-
- HY-128899
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-Auristatin E is a agent-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-135901
-
|
|
ADC Cytotoxin
Bacterial
|
Cancer
|
|
Py-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Py-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .
|
-
- HY-128941
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker .
|
-
- HY-105019A
-
|
Melphalan flufenamide hydrochloride
|
DNA Alkylator/Crosslinker
Apoptosis
|
Cancer
|
|
Melflufen (Melphalan flufenamide) hydrochloride, a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen hydrochloride shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen hydrochloride induces irreversible DNA damage and cytotoxicity in MM cells .
|
-
- HY-105019
-
|
Melphalan flufenamide
|
DNA Alkylator/Crosslinker
Apoptosis
|
Cancer
|
|
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells .
|
-
- HY-145989A
-
|
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
Aminobenzenesulfonic auristatin E TFA is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
|
-
- HY-148255
-
|
|
Apoptosis
Autophagy
|
Cancer
|
|
QN523 is a novel scaffold with agent-like properties, showing potent in vitro cytotoxicity in a panel of 12 cancer cell lines. QN523 induces apoptosis and autophagy. QN523 can be used in research of cancer .
|
-
- HY-N1243
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulysin B is a highly cytotoxic peptide and potent microtubule destabilizing agents isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin B has IC50 values in the picomolar range against many cancer cell lines, including those with multidrug resistant properties .Tubulysin B is a cytotoxic activity tubulysin which inhibits tubulin polymerization and leads to cell cycle arrest and apoptosis .
|
-
- HY-135900
-
|
|
ADC Cytotoxin
Bacterial
|
Cancer
|
|
Aniline-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Aniline-MPB-amino-C3-PBD is a sequence-selective DNA minor-groove binding agent. Aniline-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .
|
-
- HY-15579A
-
|
Monomethylauristatin F hydrochloride
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
|
-
- HY-136297
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DGN549-C consists a cleavable ADC linker valine-alanine (va) and PBD dimer. DGN549 is a novel DNA-alkylating cytotoxic payload and can be used in the synthesis of antibody-agent conjugates (ADCs) .
|
-
- HY-15044
-
|
|
PARP
|
Neurological Disease
Cancer
|
|
NU1025 is a potent PARP inhibitor with an IC50 of 400 nM and a Ki of 48 nM. NU1025 potentiates the cytotoxicity of ionizing radiation and anticancer agents. NU1025 has anti-cancer and neuroprotective activity .
|
-
- HY-108999A
-
|
BWA770U
|
DNA/RNA Synthesis
|
Cancer
|
|
Crisnatol (BWA770U) is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts .
|
-
- HY-108999
-
|
BWA770U mesylate
|
DNA/RNA Synthesis
|
Cancer
|
|
Crisnatol (BWA770U) mesylate is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol mesylate shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts .
|
-
- HY-153043
-
|
|
Drug Metabolite
|
Cancer
|
|
DM-CO-(CH2)5-SMe is an anticancer agent derived from antibody-drug conjugates (ADC) metabolite with cytotoxicity to H1703, H1975, COLO704 and Colo720E cells .
|
-
- HY-156712
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an anti EGFR monoclonal antibody (Depatuxizumab) and the cytotoxic agent Monomethyl auristatin E (MMAE). Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR .
|
-
- HY-131468
-
|
AMD473; ZD0473
|
Others
|
Cancer
|
|
Picoplatin (AMD473) is a platinum-based antineoplastic agent. Picoplatin is specifically to circumvent thiol-mediated drug resistance by sterically hindering its reaction with glutathione (GSH) while still retaining the ability to form cytotoxic lesions with DNA .
|
-
- HY-163435
-
|
|
Apoptosis
Caspase
PARP
Bcl-2 Family
|
Cancer
|
|
Anticancer agent 201 (Compound 2f) has IC50 values in the low micromolar range for multiple tumor cell lines. Anticancer agent 201 is highly cytotoxic to CCRF-CEM cells in vitro, inducing apotosis by activating caspase-3 in the intrinsic mitochondrial pathway and lysis of PARP, as well as reducing the expression of Bcl-2 and Bcl-XL proteins. Anticancer agent 201 can be used in cancer research .
|
-
- HY-139882
-
|
|
Others
|
Cancer
|
|
Anticancer agent 16 exhibits good cytotoxic activity against HCT-116, NCI-H460, and SKOV3 cell lines with IC50 8.55 μΜ, 5.41 μΜ, and 6.4 μΜ, respectively.
|
-
- HY-151447
-
|
|
Virus Protease
|
Infection
|
|
ZIKV-IN-4 (compound 5b) is a low-cytotoxicity and acid-stable anti-ZIKV agent (EC50=3.49 μM). ZIKV-IN-4 effectively inhibits the activity of ZIKV NS5 MTase .
|
-
- HY-151448
-
|
|
Virus Protease
|
Infection
|
|
ZIKV-IN-5 (compound 5c) is a low-cytotoxicity and acid-stable anti-ZIKV agent (EC50=0.71 μM). ZIKV-IN-5 effectively inhibits the activity of ZIKV NS5 MTase .
|
-
- HY-N3242
-
|
(+)-Moronic acid
|
HIV
|
Infection
|
|
Moronic acid, a triterpenoid, is an anti-HIV agent. Moronic acid inhibits viral replication with an EC50 value <1 μg/mL, and shows cytotoxicity in H9 lymphocytes with an IC50 value of 18.6 μg/mL. Moronic acid can be isolated from Brazilian propolis .
|
-
- HY-79255
-
|
|
ADC Cytotoxin
Microtubule/Tubulin
|
Cancer
|
|
Fmoc-MMAF-OMe is an anticancer agent and tubulin polymerization inhibitor with an Fmoc protecting group. The active ingredient of Fmoc-MMAF-OMe, MMAF (HY-15579), is the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs) .
|
-
- HY-144823
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 3 (compound 18) has highly inhibitory activity against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.098 μg/ml, and low cytotoxicity in normal cells. Anti-MRSA agent 3 has relatively strong ability to destroy bacterial cell wall and membrane, high binding affinity to bacterial genomic DNA .
|
-
- HY-15579
-
|
Monomethylauristatin F
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .
|
-
- HY-15579B
-
|
Monomethylauristatin F sodium
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
|
-
- HY-144655
-
|
|
Others
|
Cancer
|
|
IP2 is an immunomodulatory agent. IP2 increases PTP (Pioneer Translation Product)-derived antigen presentation in cancer cells. IP2 shows non-cytotoxic for cancer cells. IP2 induces tumor growth defects in mouse .
|
-
- HY-147933
-
|
|
Parasite
|
Infection
|
|
Antitrypanosomal agent 8 (compound 3b) has potent antitrypanosomal activity against Trypanosoma brucei with an IC50 value of 0.79 μM and exhibits certain cytotoxicity in L6 cells (IC50=80.95 μM) .
|
-
- HY-16189
-
|
NSC 264137; Celiptium
|
DNA Stain
|
Cancer
|
|
Elliptinium acetate (NSC 264137) is a DNA intercalating agent that is highly cytotoxic to L1 210 cells and covalently binds to nucleic acids from L1210 cells. Elliptinium acetate can be used in cancer research, particularly in metastatic breast cancer .
|
-
- HY-147348
-
|
|
Others
|
Cancer
|
|
4-Formylcolchicine is a potent anticancer agent. 4-Formylcolchicine shows cytotoxicity activity with IC50 values of 1.007, 0.128, 0.054 µM for A549, HT-29, HCT116 cells, respectively .
|
-
- HY-156617A
-
|
|
ADC Cytotoxin
Topoisomerase
|
Cancer
|
|
(αR)-Cyclopropaneacetamide-Exatecan (compound 2-A), an Exenotecan derivative, is a cytotoxic agent. (αR)-Cyclopropaneacetamide-Exatecan inhibits U87MG and SK-BR-3 cells proliferation, with IC50s of 8.11 and 2.31 μM .
|
-
- HY-136213
-
|
|
Fluorescent Dye
|
Others
|
|
Endoplasmic reticulum dye 1 is a promising live cell imaging agent for the detection of exocytotic events at the plasma membrane. Endoplasmic reticulum dye 1 shows low cytotoxicity, resistance to photobleaching , which is ideal for imaging either short- or long-time courses .
|
-
- HY-122751
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
(R)-DNMDP is a potent and selective cancer cell cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, binds PDE3A directly. (R)-DNMDP has a 500-fold lower EC50 compared to the (S)-enantiomer in HeLa cell line .
|
-
- HY-15142AS1
-
|
Hydroxydaunorubicin-13C,d3 TFA
|
Isotope-Labeled Compounds
Antibiotic
Endogenous Metabolite
|
Infection
Cancer
|
|
Doxorubicin- 13C,d3 (TFA) is the deuterium and 13C labeled Doxorubicin. Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stoppin
|
-
- HY-132164
-
|
|
ADC Cytotoxin
Topoisomerase
|
Cancer
|
|
Gly-7-MAD-MDCPT (compound 4b) is an anticancer agent. Gly-7-MAD-MDCPT is a Camptothecin (HY-16560) compound, it shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM .
|
-
- HY-12457
-
|
CC-1065; NSC 298223
|
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Rachelmycin (CC-1065) is an antitumor antibiotic and a DNA-alkylating agent. Rachelmycin has cytotoxic potency that can be used as a cytotoxin to synthesis ADC. Rachelmycin effectively inhibits DNA synthesis. Rachelmycin can be used for cancer and infection research .
|
-
- HY-P99967
-
|
|
ADC Antibody
|
Cancer
|
|
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .
|
-
- HY-19609
-
|
Calicheamicin γ1
|
DNA Alkylator/Crosslinker
ADC Cytotoxin
Bacterial
Apoptosis
Antibiotic
|
Infection
Cancer
|
|
Calicheamicin, an antitumor antibiotic, is a cytotoxic agent that causes double-strand DNA breaks. Calicheamicin is a DNA synthesis inhibitor . Calicheamicin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-161404
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 202 (compound 45c) is a low cytotoxic bacterial inhibitor with good activity against Gram-negative bacteria, including Escherichia coli, Klebsiella pneumonia, especially Pseudomonas aeruginosa, (MIC (minimum inhibitory concentration)=7.8-31.25 μM). Antibacterial agent 202 can exert antibacterial activity by destroying the integrity of cell membranes and can be used in the research of bacterial infections .
|
-
- HY-W011762
-
|
|
Others
|
Cancer
|
|
VK3-OCH3 is a potent antitumor agent. VK3-OCH3 shows cytotoxicity for neuroblastoma cell lines and low cytotoxicity for normal cell lines. VK3-OCH3 induces apoptosis and cell cycle arrest at G2/M phase in IMR-32 cells. VK3-OCH3 shows antitumor activity .
|
-
- HY-N4278
-
|
|
Reactive Oxygen Species
|
Inflammation/Immunology
|
|
Huangjiangsu A, pseudoprotodioscin, methyl protobioside, protodioscin, and protodeltonin, isolated from D. villosa.
Huangjiangsu A has hepatoprotective potential against H2O2-induced cytotoxicity and ROS generation and could be promising as potential therapeutic agents for liver diseases .
|
-
- HY-130626
-
|
|
RSV
Influenza Virus
|
Infection
|
|
RSV/IAV-IN-1 (compound 14e) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-1 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-1 has the potential for the research of RSV and/or IAV infections .
|
-
- HY-130627
-
|
|
RSV
Influenza Virus
|
Infection
|
|
RSV/IAV-IN-2 (compound 14c) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-2 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-2 has the potential for the research of RSV and/or IAV infections .
|
-
- HY-P99107A
-
|
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Brentuximab vedotin solution is the solution form of Brentuximab vedotin (HY-P99107). Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE) .
|
-
- HY-147881
-
|
|
Influenza Virus
|
Infection
|
|
Anti-Influenza agent 3 (compound 11h) is a potent anti-influenza agent with EC50 values of 3.29, 2.45 µM for A/HK/68 (H3N2, M2-WT), A/WSN/33 (H1N1, M2-S31N) strain, respectively. Anti-Influenza agent 3 shows low cytotoxicity for MDCK epithelial cells. Anti-Influenza agent 3 inhibits the M2 WT and S31N ion channel conductivity .
|
-
- HY-P9985
-
|
RC48
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity .
|
-
- HY-N9596
-
|
|
Bacterial
|
Infection
Cancer
|
|
Stigmasta-4,22-dien-3-one is an antitubercular agent. Stigmasta-4,22-dien-3-one shows cytotoxicity against human HT1080 tumoral cell line with an IC50 of 0.3 mM .
|
-
- HY-128930
-
|
|
ADC Linker
|
Cancer
|
|
6-O-2-Propyn-1-yl-D-galactose is a nonclaevable glycolinker for the functionalization of cytotoxic agents and applications in antibody-agent conjugation. 6-O-2-Propyn-1-yl-D-galactose is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-P9921
-
|
Ado-Trastuzumab emtansine; PRO132365; T-DM 1
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .
|
-
- HY-P9921A
-
|
Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .
|
-
- HY-146158
-
|
|
Bacterial
Potassium Channel
Antibiotic
|
Infection
|
|
WX-081, an anti-tuberculosis agent, displays excellent anti-mycobacterial activity against M. tuberculosis H37Rv and low cytotoxicity. WX-081 exhibits potent activity with MIC50s of 0.083 and 0.11 μg/mL for agent susceptible tuberculosis (DS-TB) and multidrug resistant tuberculosis (MDR-TB) strains. WX-081 also inhibits hERG channel with the IC50 of 1.89 μM.
|
-
- HY-16700
-
|
|
ADC Cytotoxin
Topoisomerase
|
Cancer
|
|
PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
|
-
- HY-N10537
-
|
|
Others
|
Cancer
|
|
Shishijimicin A is a novel antitumor agent found from the Ascidian Didemnum proliferum. Shishijimicin A shows anti-tumor activity with highly potent cytotoxicities . Shishijimicin A is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-160649
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-Gly-Gly-Phe-Gly-GABA-Exatecan is an agent linker conjugate for ADC, with an inhibitor for Topoisomerase Exatecan (HY-13631) with IC50 of 22 μM. MC-Gly-Gly-Phe-Gly-GABA-Exatecan targets various antibodies, exhibits cytotoxic and antitumor efficacy in vitro and in vivo .
|
-
- HY-154966
-
|
|
RSV
|
Infection
|
|
RSV L-protein-IN-3 is a wild-type RSV polymerase inhibitor with an IC50 value of 10.4 μM and an EC50 value of 2.1 μM (against RSV). RSV L-protein-IN-3 has lesser cytotoxicity than the clinical agent, Ribavirin (HY-B0434) .
|
-
- HY-18981
-
|
(+)-Decursin
|
|
|
|
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .
|
-
- HY-120574
-
|
|
ADC Cytotoxin
Topoisomerase
|
Cancer
|
|
TH1338 (compound 3b), an orally active camptothecin derivative and a potent chemotherapeutic agent for cancer, demonstrates excellent cytotoxic potency against human tumor cell lines in vitro. TH1338 (compound 3b) possesses significant brain penetration, favorable efflux pump properties, and hematological toxicity profile .
|
-
- HY-138540
-
|
N-Dodecylimidazole
|
Fungal
|
Cancer
|
|
1-Dodecylimidazole (N-Dodecylimidazole) is a lysosomotropic detergent and a cytotoxic agent. 1-Dodecylimidazole causes cell death by its acid-dependent accumulation in lysosomes, disruption of the lysosomal membrane, and releaseof cysteine proteases into the cytoplasm. 1-Dodecylimidazole has hypocholesterolaemic activity and broad-spectrum antifungal activity .
|
-
- HY-112732
-
|
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Sparfosic acid, a DNA antimetabolite agent, is a potent inhibitor of aspartate transcarbamoyl transferase, the enzyme catalyzing the second step of de novo pyrimidine biosynthesis. Sparfosic acid synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines .
|
-
- HY-N10539
-
|
|
Others
|
Cancer
|
|
Shishijimicin C is a novel antitumor agent found from the Ascidian Didemnum proliferum. Shishijimicin C shows anti-tumor activity with highly potent cytotoxicities . Shishijimicin C is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-N11638
-
|
|
Apoptosis
|
Cancer
|
|
Ganoderic acid R is a potent anticancer agent. Ganoderic acid R inhibits the growth by inducing apoptosis on tumor cell line. Ganoderic acid R possesses significant cytotoxicity on a multidrug resistance (MDR) tumor cell line (KB-A-1/Dox) and a sensitive tumor cell line (KB-A-1) .
|
-
- HY-153547
-
|
|
Parasite
|
Infection
Inflammation/Immunology
|
|
HSP90-IN-21 (5e) is an antiplasmodial agent, with IC50 values of 0.04, 0.17 and 2.91 μM against erythrocytic stage of P. falciparum (Pf3D7 and PfDd2 strains), cytotoxicity of human liver hepatocellular carcinoma cell line (HepG2), respectively .
|
-
- HY-15579G
-
|
Monomethylauristatin F
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .
|
-
- HY-15579BG
-
|
Monomethylauristatin F sodium
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
|
-
- HY-108391
-
|
N-Octanoyl-D-erythro-sphingosine
|
Apoptosis
PKC
Autophagy
|
Inflammation/Immunology
Cancer
|
|
C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro .
|
-
- HY-155731
-
|
|
Influenza Virus
|
Infection
|
|
Antiviral agent 35 (compound 4d) is an orally active and potent influenza virus inhibitor, acting function in the early stage of virus replication. Antiviral agent 35 inhibits ROS accumulation, autophagy and apoptosis induced by influenza virus, and also inhibits inflammatory response mediated by RIG-1 pathway in mouse model with pulmonary infection. Antiviral agent 35 shows little cytotoxicity with CC50 >800 μM in MDCK cells, and anti-H1N1 (A/Weiss/43) activity with EC50 of 2.28 μM .
|
-
- HY-15311
-
|
Abamectin; Avermectin B1a-Avermectin B1b mixt.
|
Parasite
Autophagy
Apoptosis
Reactive Oxygen Species
Antibiotic
|
Infection
Inflammation/Immunology
|
|
Avermectin B1 (Abamectin) is a mixture of two similar segments of avermectin. Avermectin B1 is an orally anti-infection agent, which can be used in the research of parasitic worms, insect pests, agriculture and animal husbandry. Avermectin B1 can also induce the production of ROS and induces cytotoxicity, apoptosis and autophagy .
|
-
- HY-128947
-
|
|
ADC Linker
|
Cancer
|
|
CL2 Linker is a cleavableADC linker. CL2-SN-38 and CL2A-SN-38 are equivalent in agent substitution (~6), cell binding (Kd ~1.2 nM), cytotoxicity (IC50 ~2.2 nM), and serum stability in vitro (t1/2 ~20 hours) .
|
-
- HY-144341
-
|
|
Bacterial
|
Infection
|
|
DprE1-IN-1 is a potent, orally active DprE1 inhibitor with favorable hepatocyte stability, low cytotoxicity and low hERG channel inhibition. DprE1-IN-1 displays potent activity against both agent-susceptible and clinically isolated drug-resistant Tuberculosis strains with MICs10 CFU reduction in macrophages.
|
-
- HY-136731
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
APE1-IN-1 is a potent and blood-brain barrier (BBB) penetrant apurinic/apyrimidinic (AP) endonuclease 1 (APE1) inhibitor with an IC50 value of 2 μM. APE1-IN-1 can potentiate the cytotoxicity of the alkylating agents Methylmethane sulfonate and Temozolomide (HY-17364) to cancer cells .
|
-
- HY-141604
-
-
- HY-161395
-
|
|
Bacterial
|
Infection
|
|
IDD-8E is an effective anti-pseudomonal agent (MIC =4.4 µM ) with no cytotoxicity. IDD-8E shows significant pseudomonal killing and disruption of pseudomonal biofilm. IDD-8E binds to the ATP-binding pocket of WaaP and also inhibits other ESKAPE pathogens.
|
-
- HY-112732B
-
|
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Sparfosic acid trisodium is a DNA antimetabolite agent and a potent inhibitor of aspartate transcarbamoyl transferase. Aspartate transcarbamoyl transferase catalyzes the second step of de novo pyrimidine biosynthesis. Sparfosic acid trisodium synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines .
|
-
- HY-N12235
-
|
|
Caspase
|
Inflammation/Immunology
|
|
Sarglaroids F (compound 6) is an anti-inflammatory agent isolated from the roots of Grass Coral. Sarglaroids F inhibits LPS/ATP-induced IL-1β release by affecting K+ efflux and reducing Caspase-1(P20) levels. Sarglaroids F is not cytotoxic to RAW264.7 cells .
|
-
- HY-12892
-
|
|
|
|
|
SKI-178 is a potent sphingosine kinase-1 (SphK1) and SphK2 inhibitor. SKI-178 is cytotoxic at IC50 concentrations ranging from 1.8 to 0.1 μM in both agent sensitive and multi-agent resistant cancer cell lines (i.e., MTR3, NCI-ADR and HL60/VCR cells). SKI-178 induces apoptosis in a CDK1-dependent manner in human acute myeloid leukemia cell lines .
|
-
- HY-15142
-
|
Hydroxydaunorubicin hydrochloride
|
Topoisomerase
ADC Cytotoxin
AMPK
Autophagy
Apoptosis
HIV
HBV
Mitophagy
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .
|
-
- HY-12098
-
|
MPC-6827 hydrochloride
|
Microtubule/Tubulin
|
Cancer
|
|
Verubulin hydrochloride (MPC-6827 hydrochloride) is a blood brain barrier permeable microtubule-disrupting agent, with potent and broad-spectrum in vitro and in vivo cytotoxic activities. Verubulin hydrochloride (MPC-6827 hydrochloride) exhibits potent anticancer activity in human MX-1 breast and other mouse xenograft cancer models. Verubulin hydrochloride (MPC 6827 hydrochloride) is a promising candidate for the treatment of multiple cancer types .
|
-
- HY-P99107
-
|
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
TNF Receptor
|
Cancer
|
|
Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma .
|
-
- HY-149346
-
|
|
Bacterial
|
Infection
|
|
Mtb-IN-2 (compound 10c) is an antimicrobial agent against Mycobacterium tuberculosis (Mtb), without cytotoxicity. Mtb-IN-2 significantly decreases colony-forming units (CFU) in spleen of murine tuberculosis models, and distinguishes both drug-sensitive and drug-resistant Mtb H37Rv strains. Mtb-IN-2 affects methionine metabolism but not folate pathway directly.
|
-
- HY-136288
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC) . Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
- HY-121300
-
|
(-)-TAN2162
|
Antibiotic
Bacterial
Endothelin Receptor
CGRP Receptor
|
Infection
Cancer
|
|
Kendomycin ((−)-TAN 2162) is a polyketide antibiotic with remarkable antibacterial and cancer cells cytotoxic activities. Kendomycin tends to be bacteriostatic rather than bactericidal and inhibits the growth of the methicillin-resistant Staphylococcus aureus (MRSA) strain COL at a low concentration (MIC of 5 μg/mL). Kendomycin is a potent antagonist of the endothelin receptor and a calcitonin receptor agonist which plays its role as an anti-osteoporotic agent .
|
-
- HY-P99542
-
|
SAR-408701; HuMAb2-3-SPDB-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
|
-
- HY-117512
-
|
|
Dopamine Transporter
Serotonin Transporter
|
Neurological Disease
|
|
UWA-101 hydrochloride is a selective and non-cytotoxic DAT/SERT inhibitor, with EC50 values of 3.6 µM and 2.3 µM for inhibiting DAT and SERT, respectively. UWA-101 hydrochloride can alleviate the side effects of dopaminergic agents (such as L-DOPA), such as motor disorders, and lacks psychotropic activity. UWA-101 hydrochloride can be used for research on neurodegenerative diseases such as Parkinson's disease .
|
-
- HY-125136
-
|
(-)-Chaetominine
|
PI3K
Akt
Keap1-Nrf2
|
Cancer
|
|
Chaetominine is an alkaloidal metabolite. Chaetominine has cytotoxicity against human leukemia K562 and colon cancer SW1116 cell lines. Chaetominine reduces MRP1-mediated agent resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells .
|
-
- HY-148170
-
|
|
EBV
DNA/RNA Synthesis
Nucleoside Antimetabolite/Analog
|
Infection
|
|
L-I-OddU, a L-5'-halo- dioxolane nucleoside analogue, is a potent and selective anti-Epstein-Barr virus (EBV) agent with an EC50 value of 0.03μM. L-I-OddU has low cytotoxicity with a CC50 value of 1000 nM. L-I-OddU has antiviral activity by suppressing replicative EBV DNA and viral protein synthesis .
|
-
- HY-U00244A
-
|
P2647 hydrochloride; BZQ hydrochloride; Benzoquinamide hydrochloride
|
Adrenergic Receptor
|
Cancer
|
|
Benzquinamide (P2647) is an antiemetic which can bind to the α2A, α2B, and α2C adrenergic receptors (α2-AR) with Ki values of 1,365, 691, and 545 nM, respectively. Benzquinamide also inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells .
|
-
- HY-16700G
-
|
|
ADC Cytotoxin
Topoisomerase
|
Cancer
|
|
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
|
-
- HY-128942
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 agent linker. MAC glucuronide α-hydroxy lactone-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 99 and 105 ng/mL, respectively .
|
-
- HY-146087
-
|
|
Autophagy
|
Cancer
|
|
Autophagy inducer 4 is a Magnolol-based Mannich base derivatives, which can be used as an anticancer agent. Autophagy inducer 4 suppresses cancer cells via inducing autophagy. Autophagy inducer 4 has 76-fold improvement in cytotoxicity against T47D cells compared with Magnolol. Autophagy inducer 4 also possesses suppressive effects on migration of T47D and Hela cancer cells .
|
-
- HY-B0608R
-
|
|
Bacterial
Antibiotic
Apoptosis
Necroptosis
|
Infection
Cancer
|
|
Chlorhexidine (digluconate) (Standard) is the analytical standard of Chlorhexidine (digluconate). This product is intended for research and analytical applications. Chlorhexidine digluconate is a chlorophenyl biguanide with broad antibacterial action against both Gram (+) and (-) bacteria and fungi. Chlorhexidine digluconate is a broad-spectrum antiseptic and disinfectant. Chlorhexidine digluconate is effective to prevent and control infectious diseases of the mouth by killing bacteria in saliva and tongue. Chlorhexidine digluconate is a cytotoxic agent and induces cell necrosis and apoptosis .
|
-
- HY-B1064
-
|
Clindamycin 2-phosphate; U-28508
|
Bacterial
Antibiotic
Parasite
|
Infection
|
|
Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis .Clindamycin phosphate has no cytotoxicity。 Combined with platelet rich fibrin (PRF), PRF-Clindamycin phosphate enhances antimicrobial properties .
|
-
- HY-146226
-
|
|
Enterovirus
|
Infection
|
|
Viral 2C protein inhibitor 1 (compound 6aw) is a potent and broad-spectrum enterovirus antiviral agent, inhibiting viral 2C protein. Viral 2C protein inhibitor 1 inhibits multiple strains of EV-D68, EV-A71 and CVB3 with EC50s of 0.1~3.6 µM, and exhibits high selectivity index and relatively low cytotoxicity .
|
-
- HY-149263
-
|
|
Influenza Virus
Virus Protease
|
Infection
|
|
HAA-09 is an orally active and potent anti-influenza agent, targeting the influenza PB2_cap binding domain. HAA-09 displays potent anti-influenza A virus activity, with an EC50 of 0.03 μM. HAA-09 shows polymerase inhibition, with an IC50 of 0.06±0.004 μM. HAA-09 blocks virus replication without causing obvious cytotoxicity .
|
-
- HY-128943
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) agent linker. MAC glucuronide phenol-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 113 and 67 ng/mL, respectively.Albumin-coupled MAC glucosidol-linked SN-38 shows good stability in mouse plasma .
|
-
- HY-128952
-
|
SG3249
|
Drug-Linker Conjugates for ADC
DNA Alkylator/Crosslinker
|
Cancer
|
|
Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
|
-
- HY-129379
-
|
|
ADC Cytotoxin
|
Cancer
|
|
DC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by alkylation of adenine residues by its propabenzindole (CBI) component .
|
-
- HY-15142A
-
|
Hydroxydaunorubicin
|
ADC Cytotoxin
Antibiotic
Bacterial
Topoisomerase
AMPK
HIV
Autophagy
Mitophagy
Apoptosis
HBV
|
Infection
Cancer
|
|
Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy . Doxorubicin inhibits human DNA topoisomerase I with an IC50 of 0.8 μM .
|
-
- HY-143744
-
|
|
Influenza Virus
|
Infection
|
|
Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .
|
-
- HY-143743
-
|
|
Influenza Virus
|
Infection
|
|
Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28) .
|
-
- HY-143755
-
|
|
Influenza Virus
|
Infection
|
|
Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1) .
|
-
- HY-D0190
-
|
HTTA; TTA; TTFA
|
Biochemical Assay Reagents
|
Infection
Others
Cancer
|
|
2-Thenoyltrifluoroacetone is a chelating agent. 2-Thenoyltrifluoroacetone can be used for the complexation of various metal ions including Mn(II), Co(III), Ni(II), et al.. 2-Thenoyltrifluoroacetone possesses antitubercular and cytotoxic activities. 2-Thenoyltrifluoroacetone is also used as common inhibitor of mitochondrial electron flux and to analyze the endothelial cell dysfunction. Besides, copper (II) complex of 2-Thenoyltrifluoroacetone has anticancer activity against K562 .
|
-
- HY-156348
-
|
|
Monoamine Oxidase
Autophagy
Apoptosis
Cholinesterase (ChE)
|
Neurological Disease
|
|
MAO-B-IN-26 (Compound IC9) is a MAO-B and acetylcholinesterase inhibitor. MAO-B-IN-26 protects SH?SY5Y cells against Aβ induced cytotoxicity, morphological changes, ROS generation and membrane damage. MAO-B-IN-26 also inhibits Aβ induced autophagy and apoptosis. MAO-B-IN-26 can be used as a neuroprotective agent against Alzheimer’s disease .
|
-
- HY-101287
-
|
|
|
|
|
MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line .
|
-
- HY-114778
-
|
SHR3162; Fuzuloparib
|
PARP
|
Cancer
|
|
Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC50=1.46±0.72 nM, a cell‐free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)‐deficient cells, and sensitizes both HR‐deficient and HR‐proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .
|
-
- HY-124623
-
|
|
Parasite
|
Infection
|
|
DNDI-8219 (compound 58) is a potent selective and orally active trypanocidal agent, possessing inhibitory activity against Trypanosoma cruzi (T. cruzi) with an IC50 of 0.4 μM. DNDI-8219 has low cytotoxicity (L6 cells IC50 > 100 μM). DNDI-8219 can effectively cure chronic T. cruzi infection and markedly reduce parasite burdens in mouse model. DNDI-8219 has good solubility, metabolic stability and safety.
|
-
- HY-P99612
-
|
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
-
- HY-133147
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
HDAC3/6-IN-2 (compound 15) is a potent HDAC6 and HDAC3 inhibitor, with IC50 values of 0.368 and 0.635 μM, respectively. HDAC3/6-IN-2 shows antitumor activity, and induces cancer cell apoptosis. HDAC3/6-IN-2 decreases the levels of HDAC6 and HDAC3, associated with upregulation of acetylated H3 and α-tubulin .
|
-
- HY-N11650
-
|
|
Bacterial
|
Infection
|
|
(22S,24E)-3β,22-Diacetoxylanosta-7,9(11),24-trien-26-oic acid (compound 15) is an antitubercular agent with MIC value of 12.5 μg/mL for Mycobacterium tuberculosis H37Ra. (22S,24E)-3β,22-Diacetoxylanosta-7,9(11),24-trien-26-oic acid shows cytotoxicity with IC50 value of 32 μM for Vero cells .
|
-
- HY-150644
-
|
|
Others
|
Cancer
|
|
S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells .
|
-
- HY-N3387
-
|
|
Apoptosis
NF-κB
Akt
MMP
|
Inflammation/Immunology
Cancer
|
|
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC50=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer . Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect . Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo . Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations .
|
-
- HY-155718
-
|
|
Apoptosis
|
Cancer
|
|
fac-[Re(CO)3(L6)(H2O)][NO3] (compound 6), the rhenium(I) tricarbonyl aqua complex, is an anticancer agent associated with mitochondrial dysfunction. fac-[Re(CO)3(L6)(H2O)][NO3] is cytotoxic to prostate cancer cells, IC50=50 nM (PC-3 cells). fac-[Re(CO)3(L6)(H2O)][NO3] mainly accumulates in the nucleus, down-regulates ATP production in PC3 cells, and promotes apoptosis. However, fac-[Re(CO)3(L6)(H2O)][NO3] did not induce necrosis, pyrodeath and autophagy .
|
-
![fac-[Re(CO)3(L6)(H2O)][NO3]](//file.medchemexpress.com/product_pic/hy-155718.gif)
- HY-155719
-
|
|
Paraptosis
|
Cancer
|
|
fac-[Re(CO)3(L3)(H2O)][NO3] (compound 3), the rhenium(I) tricarbonyl aqua complex, is an anticancer agent associated with mitochondrial dysfunction. fac-[Re(CO)3(L3)(H2O)][NO3] is cytotoxic to prostate cancer cells with IC50=0.32 μM (PC-3 cells). fac-[Re(CO)3(L3)(H2O)][NO3] mainly accumulates in mitochondria, down-regulates ATP production in PC3 cells, and promotes paraptosis. However, fac-[Re(CO)3(L3)(H2O)][NO3] did not induce necrosis, apoptosis and autophagy .
|
-
![fac-[Re(CO)3(L3)(H2O)][NO3]](//file.medchemexpress.com/product_pic/hy-155719.gif)
-
-
HY-L023
-
|
|
92 compounds
|
|
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.
The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 92 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.
|
| Cat. No. |
Product Name |
Type |
-
- HY-136213
-
|
|
Dyes
|
|
Endoplasmic reticulum dye 1 is a promising live cell imaging agent for the detection of exocytotic events at the plasma membrane. Endoplasmic reticulum dye 1 shows low cytotoxicity, resistance to photobleaching , which is ideal for imaging either short- or long-time courses .
|
-
- HY-15579G
-
|
Monomethylauristatin F (GMP)
|
Fluorescent Dye
|
|
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .
|
-
- HY-15579BG
-
|
Monomethylauristatin F sodium (GMP)
|
Fluorescent Dye
|
|
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
|
-
- HY-16700G
-
|
|
Fluorescent Dye
|
|
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
|
| Cat. No. |
Product Name |
Type |
-
- HY-138540
-
|
N-Dodecylimidazole
|
Cell Assay Reagents
|
|
1-Dodecylimidazole (N-Dodecylimidazole) is a lysosomotropic detergent and a cytotoxic agent. 1-Dodecylimidazole causes cell death by its acid-dependent accumulation in lysosomes, disruption of the lysosomal membrane, and releaseof cysteine proteases into the cytoplasm. 1-Dodecylimidazole has hypocholesterolaemic activity and broad-spectrum antifungal activity .
|
-
- HY-15579G
-
|
Monomethylauristatin F (GMP)
|
Biochemical Assay Reagents
|
|
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .
|
-
- HY-15579BG
-
|
Monomethylauristatin F sodium (GMP)
|
Biochemical Assay Reagents
|
|
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
|
-
- HY-P2965
-
|
|
Biochemical Assay Reagents
|
|
L-Lysine α-oxidase is a potent anticancer agent. L-Lysine α-oxidase also a L-amino acid oxidase, deaminates L-lysine with the yield of H2O2, ammonia, and α-keto-ε-aminocaproate. L-Lysine α-oxidase shows cytotoxicity and anticancer activity .
|
-
- HY-16700G
-
|
|
Biochemical Assay Reagents
|
|
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-105019
-
|
Melphalan flufenamide
|
DNA Alkylator/Crosslinker
Apoptosis
|
Cancer
|
|
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells .
|
-
- HY-P2965
-
|
|
Peptides
|
Cancer
|
|
L-Lysine α-oxidase is a potent anticancer agent. L-Lysine α-oxidase also a L-amino acid oxidase, deaminates L-lysine with the yield of H2O2, ammonia, and α-keto-ε-aminocaproate. L-Lysine α-oxidase shows cytotoxicity and anticancer activity .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99152
-
|
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .
|
-
- HY-P9968
-
|
|
EGFR
|
Cancer
|
|
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
- HY-P99967
-
|
|
ADC Antibody
|
Cancer
|
|
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .
|
-
- HY-P99542
-
|
SAR-408701; HuMAb2-3-SPDB-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
|
-
- HY-P99612
-
|
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-15142AS1
-
|
|
|
Doxorubicin- 13C,d3 (TFA) is the deuterium and 13C labeled Doxorubicin. Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stoppin
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-136288
-
|
|
|
Azide
|
|
Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC) . Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
- HY-128930
-
|
|
|
Alkynes
ADC Synthesis
|
|
6-O-2-Propyn-1-yl-D-galactose is a nonclaevable glycolinker for the functionalization of cytotoxic agents and applications in antibody-agent conjugation. 6-O-2-Propyn-1-yl-D-galactose is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![fac-[Re(CO)3(L6)(H2O)][NO3]](http://file.medchemexpress.com/product_pic/hy-155718.gif)
![fac-[Re(CO)3(L3)(H2O)][NO3]](http://file.medchemexpress.com/product_pic/hy-155719.gif)
